A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 14 Dec 2017
At a glance
- Drugs Cabozantinib (Primary)
- Indications CNS cancer; Solid tumours; Thyroid cancer
- Focus Adverse reactions
- 11 Dec 2017 Planned End Date changed from 31 Oct 2017 to 31 Oct 2018.
- 11 Dec 2017 Planned primary completion date changed from 31 Oct 2017 to 31 Oct 2018.
- 18 Mar 2017 Results of a population pharmacokinetic model of Cabozantinib in pediatric patients with reccurent or refractory solid tumors, presented at the 118th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.